Инфекционный и стерильный эндофтальмит после интравитреальных инъекций: дифференциальная диагностика, профилактика, лечение

Обложка

Цитировать

Полный текст

Аннотация

Эндофтальмит — редкое, но крайне тяжёлое осложнение различных внутриглазных вмешательств. В статье проанализированы данные мировой литературы о частоте возникновения, дифференциальной диагностике, методах профилактики и лечения эндофтальмитов после интравитреальных инъекций.

Об авторах

Юрий Сергеевич Астахов

ФГБОУ ВО «ПСПбГМУ им. И.П. Павлова» Минздрава России

Автор, ответственный за переписку.
Email: astakhov73@mail.ru

д-р мед. наук, профессор, кафедра офтальмологии с клиникой

Россия, Санкт-Петербург

Светлана Георгиевна Белехова

ФГБОУ ВО «ПСПбГМУ им. И.П. Павлова» Минздрава России

Email: beleksv@yandex.ru

ассистент кафедры офтальмологии, врач офтальмолог, клиника офтальмологии

Россия, Санкт-Петербург

Екатерина Александровна Литвинова

ФГБОУ ВО «ПСПбГМУ им. И.П. Павлова» Минздрава России

Email: evgenica159@mail.ru

ординатор кафедры офтальмологии, клиника офтальмологии

Россия, Санкт-Петербург

Список литературы

  1. Агеева Е.В., Гродненская А.Е., Попова К.А. Роль профилактического назначения местных антибактериальных препаратов перед интравитреальной инъекцией // Офтальмологические ведомости. – 2015. – Т. 8. – № 2. – С. 80–83. [Ageeva EV, Grodnenskaya AE, Popova KA. Therole of preventive topical antibiotic treatment prior to intravitreal injection. Oftal’mologicheskie vedomosti. 2015;8(2)80-83. (In Russ.)]
  2. Астахов С.Ю., Вохмяков A.B. Эндофтальмит: профилактика, диагностика, лечение // Офтальмологические ведомости. – 2008. – Т. 1. – № 1. – С. 35–45. [Astakhov SYu, Vokhmyakov AB. Endoftal’mit: profilaktika, diagnostika, lechenie. Oftal’mologicheskie vedomosti. 2008;1(1):35-45. (In Russ.)]
  3. Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal Anti-VEGF pharmacotherapy. Hindawi Publishing Corporation Mediators of Inflammation. 2013; ArticleID943409, 6 pages doi: 10.1155/2013/943409.
  4. Ang GS, Varga Z, Shaarawy. Postoperative infection in penetrating versus non-penetrating glaucoma surgery. Br J Ophthalmol. 2010;94:1571-76. doi: 10.1136/bjo.2009.163923.
  5. Barry P, Cordovés L, Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. Ireland, The European Society of Cataract and Refractive Surgeons; 2013.
  6. Casparis H, Wolfensberger TJ, Becker M, et al. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. Retina. 2014;34(1):12-7. doi: 10.1097/IAE.0b013e31829f74b0.
  7. Cheung CS, Wong AW, Lam WС. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119:1609-14. doi: 10.1016/j.ophtha.2012.02.014.
  8. Chong DY, Anand R, Williams PD, et al. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina. 2010;30(9):1432-40. doi: 10.1097/IAE.0b013e3181dc04da.
  9. Cohen SM, Flynn Jr HW, Murray TG, Smiddy WE. Endophthalmitis after pars plana vitrectomy. The Postvitrectomy Endophthalmitis Study Group. Ophthalmology. 1995;102:705-12. doi: 10.1016/S0161-6420(95)30965-7.
  10. Martin DF, Maguire MG, Fine SL, et al. Comparison of Age-related Macular Degeneration Treatments Trials (CATT), Research. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053.
  11. Cottingham AJ, Forster RK. Vitrectomy in endophthalmitis: result of study using vitrectomy, intraocular antibiotics, or a combination of both. Arch Ophtalmol. 1976;94:2078-81. doi: 10.1001/archopht.1976.03910040738007.
  12. Dave SB, Toma HS, Kim SJ. Changes in ocular flora in eyes exposed to ophthalmic antibiotics. Ophthalmology. 2013;120(5):937-4
  13. Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152:266-72. doi: 10.1016/j.ajo.2011.01.053.
  14. Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33(6):978-88. doi: 10.1016/j.jcrs.2007.02.032.
  15. Eifrig C, Scott I, et al. Аcute-onset postoperative endophthalmitis: Review of incidence and visual outcomes (1995-2001). Ophthalmic Surg Lasers. 2002;33:373-378.
  16. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479-96. doi: 10.1001/archopht.1995.01100120009001
  17. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008;28:1395-9. doi: 10.1097/IAE.0b013e3181884fd2.
  18. Forster RK. Experimental postoperative endophthalmitis. Trans Ophtalmol. 1992;90:505-559.
  19. Friedman DA, et al. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina. 2013;33(5):975-81. doi: 10.1097/IAE.0b013e3182877585.
  20. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-49. doi: 10.1136/bjo.2006.099598.
  21. Georgopoulos M, Polak K, Prager F, et al.. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93(4):457-62. doi: 10.1136/bjo.2008.138479.
  22. Haas W, Pillar CM, Torres M, et al. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol. 2011;152(4):567-74. doi: 10.1016/j.ajo.2011.03.010.
  23. Hahn P. Aflibercept — related sterile inflammation. Ophthalmology. 2013;120(5):1100-101. doi: 10.1016/j.ophtha.2012.11.018.
  24. Hahn P, Chung MM, Flynn HW Jr. Postmarketing Analysis of Aflibercept-Related Sterile Intraocular Inflammation. JAMA Ophthalmol. 2015;133(4):421-426. doi: 10.1001/jamaophthalmol.2014.5650.
  25. Hamill MB, Osato MS, Wilhelmus KR. Experimental evaluation of chlorhexidine gluconate for ocular antisepsis. Antimicrob Agents Chemother. 1984;26(6):793-6. doi: 10.1128/AAC.26.6.793.
  26. Hatch WV, Cernat G, Wong D, et al. Risk factors for acute endophthalmitis after cataract surgery: a population-based study. Ophthalmology. 2009;116:425-30. doi: 10.1016/j.ophtha.2008.09.039.
  27. Heier J, Brown D, Chong V, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology. 2012;119:2537-48. doi: 10.1016/j.ophtha.2012.09.006.
  28. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. Journal of Interferon and Cytokine Research. 1997;17(1)15-21.
  29. Hoevenaars NED, Gans D, Missotten T, et al. Suspected bacterial endophthalmitis following intravitreal anti-VEGF injection: Case series and literature review. Ophthalmologica. 2012;228:143-47. doi: 10.1159/000339584.
  30. Hsu J, Gerstenblith AT, Garg SJ, Vander JF. Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics. Am J Ophthalmol. 2014;157(3):514-8. doi: 10.1016/j.ajo.2013.10.003.
  31. Isenberg SJ, Apt L, Yoshimori R, Khwarg S. Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol. 1985;103(9):1340-2. doi: 10.1001/archopht.1985.01050090092039.
  32. Jager R, Aiello L, Patel S, Cunningham E. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676-98. doi: 10.1097/00006982-200410000-00002.
  33. Jager RD, Timothy N, Coney G, et al. Endophthalmitis as a complication of intravitreal injection: a systemic review. Presented at ARVO, Ft. Lauderdale. 2004, abs. 2001.
  34. Jonas JB, Spandau UH, Rensch F, et al. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther. 2007;23:240-2. doi: 10.1089/jop.2006.0146.
  35. Kattan HM, Flynn HW. Nosocomial endophtalmitis survey. Сurrent incidence of infection after intraocular surgery. Ophtalmology. 1991;98:227-38.
  36. Katz LJ, Сantor LB, Spaech GL. Complications of surgery in glaucoma: Early and late bacterial endophthalmitis following glaucoma filtering surgery. Ophthalmology. 1985;92:959-63.
  37. Khan RI, Kennedy S, Barry P. Incidence of presumed postoperative endophthalmitis in Dublin for a 5-year period (1997-2001). J Cataract Refract Surg. 2005;31:1575-81. doi: 10.1016/j.jcrs.2005.01.031.
  38. Koc F, Sen E, Demirbay P, et al. Factors influencing treatment result in pseudophakic endophtalmitis. Eur J Оphtalmol. 2002;12:34-9.
  39. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans — Clinical significance, assessment and prediction. Current Pharmaceutical Biotechnology. 2002;3(4):349-60. doi: 10.2174/1389201023378175.
  40. Kunimoto DY, Kaiser RS, Wills Eye Retina Service. Incidence of endophthalmitis after 20- and 25-gauge vitrectomy. Ophthalmology. 2007;114(12):2133-37. doi: 10.1016/j.ophtha.2007.08.009.
  41. Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: Our experience after 2,000 injections. Retina. 2009;29(3)313-18.
  42. Lemley CA, Han DP. Endophthalmitis: a review of current evaluation and management. Retina. 2007;27(6):662-680. doi: 10.1097/IAE.0b013e3180323f96.
  43. Mason JO. III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-67. doi: 10.1097/IAE.0b013e3181633fee.
  44. Moshfeghi A, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: A six-year experience at a university referral center. Retina. 2011;31:662-8. doi: 10.1097/IAE.0b013e31821067c4.
  45. Moshirfar M, Feiz V, Vitale AT, et al. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series. Ophthalmology. 2007;114(4):686-91. doi: 10.1016/j.ophtha.2006.08.038.
  46. Nelson DM. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina. 2003;23(5):686-91. doi: 10.1097/00006982-200310000-00014.
  47. Peyman G, Lee P, Seal DV. Endophthalmitis – diagnosis and management. Taylor & Francis, London. 2004:1-270. doi: 10.3109/9780203017630-2.
  48. Pleyer U, Mondino BJ, Adamu SA, et al. Immune response to Staphylococcus epidermidis endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci. 1992;33:2650-63.
  49. Ramulu PY, Do DV, Corcoran KJ, et al. Use of retinal procedures in Medicare beneficiaries from 1997 to 2007. Arch Ophthalmol. 2010;128:1335-40. doi: 10.1001/archophthalmol.2010.224.
  50. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145(5):879-82. doi: 10.1016/j.ajo.2007.12.036.
  51. Roth DB, Lee SS, Flynn HW, Jr. Inflammatory reactions after intravitreal triamcinolone acetonide: Possible mechanisms and therapeutic options. Expert Rev Ophthalmol. 2010;5(3):273-76. doi: 10.1586/eop.10.20.
  52. Roth DB, Modi КK, Flynn HW Jr. Distinguishing Infection Post-Intravitreal Injection. Review of Ophthalmology. 2013;20(7):1-42.
  53. Scott IU, Flynn HW Jr, Dev S, et al. Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: incidence and outcomes. Retina. 2008;28:138-42. doi: 10.1097/IAE.0b013e31815e9313.
  54. Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028-34. doi: 10.1016/j.ophtha.2011.02.034.
  55. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008;86:372-6. doi: 10.1111/j.1600-0420.2007.01067.x.
  56. Somani S, Grinbaum A, Slomovic AR. Post-operative endophthalmitis: incidence, predisposing surgery, clinical course and outcome. Can J Ophthalmol. 1997;32:303-10.
  57. Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98:1769-75. doi: 10.1016/S0161-6420(91)32052-9.
  58. Stepien KE, Eaton AM, Jaffe GJ, et al. Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in Spring 2006. Retina. 2009;29:207-13. doi: 10.1097/IAE.0b013e31818eccb3.
  59. Storey P, Dollin M, Pitcher J, et al. Post-Injection Endophthalmitis Study T. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014;121(1):283-9. doi: 10.1016/j.ophtha.2013.08.037.
  60. Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol. 2005;123(5):613-20. doi: 10.1001/archopht.123.5.613.
  61. Taban M, Singh RP, Chung JY, et al. Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis. Am J Ophthalmol. 2007;144:50-4. doi: 10.1016/j.ajo.2007.03.051.
  62. Talley AR, D, Amico DJ, Talamo JH. The role of vitrectomy in the treatment of the postoperative endophthalmitis: of a experimental study. Arch Ophtalmol. 1987;105:1699-1702. doi: 10.1001/archopht.1987.01060120097034.
  63. Whitacre MM, Crockett RS. Tolerance of intravitreal povidone-iodine in rabbit eyes. Curr Eye Res. 1990;9(8):725-32. doi: 10.3109/02713689008999567.
  64. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2008;115(11):1911-15. doi: 10.1016/j.ophtha.2008.05.007.
  65. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe’s Arch Clin Exp Ophthalmol. 2008;46:81-7.
  66. Wykoff C, Flynn H Jr, Rosenfeld P. Prophylaxis for endophthalmitis following intravitreal injection: antisepsis and antibiotics. Am J Ophthalmol. 2011;155(5):717-9. doi: 10.1016/j.ajo.2011.07.002.
  67. Yamashiro K, Tsujikawa A, Miyamoto K, et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina. 2010;30(3):485-90. doi: 10.1097/IAE.0b013e3181bd2d51.

© Астахов Ю.С., Белехова С.Г., Литвинова Е.А., 2017

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах